Please use this identifier to cite or link to this item:
|標題:||Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy||作者:||Chen, D.Y.
|關鍵字:||tumor-necrosis-factor;factor-kappa-b;proinflammatory cytokines;joint;inflammation;double-blind;t-cells;matrix metalloproteinases;cartilage destruction;synovial fibroblasts;dependent pathway||Project:||Arthritis Research & Therapy||期刊/報告no：:||Arthritis Research & Therapy, Volume 13, Issue 4.||摘要:||
Introduction: The objective of this study was to investigate the effects of tumor necrosis factor (TNF)-alpha inhibitors on circulating T helper-type 17 (Th17) cells and Th17-related cytokines in patients with rheumatoid arthritis (RA). Methods: The frequencies of circulating Th17 cells and serum levels of Th17-related cytokines were determined using flow cytometry analysis and ELISA, respectively, in 48 RA patients both before (baseline) and six months after anti-TNF-alpha therapy. Therapeutic response was evaluated using European League Against Rheumatism (EULAR) response criteria. Results: Significantly higher baseline frequencies of circulating Th17 cells and serum levels of interleukin (IL)-6, IL17, IL-21, IL-23 and TNF-alpha were observed in active RA patients than in 12 healthy controls (all P < 0.001). After anti-TNF-alpha therapy, 36 patients (75%) were EULAR responders (20 good responders and 16 moderate responders) and 12 (25.0%) were non-responders. The mean levels of circulating Th17 cells and IL-17 significantly decreased (1.13% vs. 0.79%; 43.1 pg/ml vs. 27.8 pg/ml; respectively, both P < 0.001) in parallel with clinical remission in responders. Levels of IL-6, IL-21, IL-23 and TNF-alpha were significantly decreased after anti-TNF-alpha therapy in responders. In contrast, the mean levels of circulating Th17 cells and IL-17 significantly increased after anti-TNF-alpha therapy (2.94% vs. 4.23%; 92.1 pg/ml vs. 148.6 pg/ml; respectively, both P < 0.05) in non-responders. Logistic regression analysis identified a high baseline level of IL-17 as a significant predictor of poor therapeutic response. Conclusions: The beneficial effect of anti-TNF-alpha therapy might involve a decrease in Th17-related cytokines in responders, whereas rising levels of circulating Th17-cells and IL-17 were observed in patients with an inadequate response to anti-TNF-alpha therapy.
|Appears in Collections:||生物醫學研究所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.